Risankizumab治疗克罗恩病的多中心真实世界结局:RESOLVE IG-IBD研究
该多中心回顾性观察队列纳入520例启动Risankizumab治疗的成人克罗恩病患者,评估第12、26、52周疗效与安全性。第12周无激素临床缓解率为60.8%,第52周为65.6%,内镜缓解率为37.5%;乌司奴单抗初治患者早期临床结局及第52周内镜缓解率显著优于经治患者。Risankizumab耐受良好,未发现新安全信号。
要点
- 第12周无激素临床缓解率60.8%,第52周为65.6%。
- 第52周内镜缓解率37.5%,影像学缓解24.6%,透壁愈合9.8%。
- 乌司奴单抗初治者第12周无激素临床缓解69.8%,经治者53.3%。
核心结论
- 在大型难治性真实世界克罗恩病人群中,Risankizumab诱导快速且持续的临床、内镜和影像学良好结局。
- 既往2次与≥3次治疗失败患者的1年疗效相当,支持Risankizumab作为难治人群的有价值选择。
研究设计与样本
- 多中心、回顾性观察性队列研究。
- 纳入520例启动Risankizumab治疗的成人克罗恩病患者,在第12、26、52周进行评估。
- 主要疗效分析采用实际观察法;预设敏感性分析纳入数据库锁定前预期达到第52周的患者,并采用无应答者填补。
主要发现
- 第12周临床应答率为76.5%,无激素临床缓解率为60.8%。
- 第52周无激素临床缓解率为65.6%,内镜缓解率为37.5%,影像学缓解率为24.6%,透壁愈合率为9.8%。
- 乌司奴单抗初治患者第12周无激素临床缓解率为69.8%,经治患者为53.3%;第52周内镜缓解率分别为56.5%和28.6%。
- 肠外表现随时间减少,肛周疾病轻度改善。
- 敏感性队列(N=213)第52周无激素临床缓解率为47%。
关键数值与推荐
- 无激素临床缓解定义为Harvey-Bradshaw指数<5且未使用全身性皮质类固醇或布地奈德。
- 内镜缓解定义为简化内镜评分-CD 0-2分或术后Rutgeerts i0-i1。
临床怎么用
- Risankizumab可用于难治性克罗恩病,包括既往多次治疗失败的患者。
- 乌司奴单抗初治患者可能获得更优的早期临床应答和内镜缓解。
局限性
- 回顾性观察性设计。
- 主要疗效分析采用实际观察法,可能存在偏倚。
- 敏感性分析采用无应答者填补,第52周无激素临床缓解率为47%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: To assess the effectiveness and safety of Risankizumab (RZB) in a large, nationwide real-world cohort of patients with Crohn's disease (CD). METHODS: We conducted a multicenter, retrospective observational cohort of adults initiating RZB with assessments at weeks 12, 26, and 52. Coprimary end points were (i) week-12 steroid-free clinical remission (SFCR) (Harvey-Bradshaw Index <5 in the absence of systemic corticosteroids or budesonide) and (ii) week-52 endoscopic remission (Simple Endoscopic Score-CD 0-2 or Rutgeerts i0-i1 postoperatively). The main effectiveness analysis was as-observed; a preplanned sensitivity analysis included patients expected to reach week-52 before database lock and applied nonresponder imputation. RESULTS: We included 520 patients, 45.0% failed ≥3 and 54.8% were ustekinumab (UST)-exposed. At week 12, clinical response was 76.5% and 60.8% achieved SFCR. By week 52, SFCR was 65.6%; endoscopic remission occurred in 37.5%, whereas radiologic remission and transmural healing were 24.6% and 9.8%, respectively. UST-naïve patients showed significantly superior early clinical outcomes (week-12 SFCR: 69.8% vs 53.3%) and a higher rate of endoscopic remission at week 52 (56.5% vs 28.6%) compared with UST-exposed patients. Notably, week-52 effectiveness was comparable between patients with 2 and those with ≥3 previous failures. Extraintestinal manifestations decreased over time, whereas perianal disease improved modestly. In the sensitivity cohort (N = 213), SFCR was 47% at week-52. RZB was well-tolerated with no new safety signals identified. DISCUSSION: In a large, refractory, real-world CD population, RZB induced rapid and sustained favorable clinical, endoscopic, and radiologic outcomes. Importantly, one-year effectiveness was similar in patients with 2, and ≥3 previous failures, supporting RZB as a valuable option for a refractory population.
引用
- Scaldaferri F, Di Vincenzo F, Aloi M, et al. Multicenter Real-World Outcomes of Risankizumab in Crohn's Disease: The RESOLVE IG-IBD Study. Am J Gastroenterol. 2026. PMID: 41705712. doi:10.14309/ajg.0000000000003969
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。